CSF-1R inhibitor

DRUG CLASS:

CSF-1R inhibitor

News alerts, weekly reports and conference planners

Related drugs:

PDGFRA D842V	Gastrointestinal Stromal Tumor	PDGFRA D842V	Gastrointestinal Stromal Tumor	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1
PDGFRA exon 18 mutation	Gastrointestinal Stromal Tumor	PDGFRA exon 18 mutation	Gastrointestinal Stromal Tumor	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1
No biomarker	Tenosynovial Giant Cell Tumor	No biomarker	Tenosynovial Giant Cell Tumor	pexidartinib Sensitive: A1 - Approval pexidartinib Sensitive : A1	pexidartinib Sensitive: A1 - Approval pexidartinib Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	CS 2164 Sensitive: B - Late Trials CS 2164 Sensitive : B	CS 2164 Sensitive: B - Late Trials CS 2164 Sensitive : B
PDGFRA mutation	Gastrointestinal Stromal Tumor	PDGFRA mutation	Gastrointestinal Stromal Tumor	avapritinib Sensitive: C2 – Inclusion Criteria avapritinib Sensitive : C2	avapritinib Sensitive: C2 – Inclusion Criteria avapritinib Sensitive : C2
KIT mutation	Gastrointestinal Stromal Tumor	KIT mutation	Gastrointestinal Stromal Tumor	avapritinib Sensitive: C2 – Inclusion Criteria avapritinib Sensitive : C2	avapritinib Sensitive: C2 – Inclusion Criteria avapritinib Sensitive : C2
MET amplification	Gastric Cancer	MET amplification	Gastric Cancer	TPX-0022 Sensitive: C2 – Inclusion Criteria TPX-0022 Sensitive : C2	TPX-0022 Sensitive: C2 – Inclusion Criteria TPX-0022 Sensitive : C2
MET mutation	Gastric Cancer	MET mutation	Gastric Cancer	TPX-0022 Sensitive: C2 – Inclusion Criteria TPX-0022 Sensitive : C2	TPX-0022 Sensitive: C2 – Inclusion Criteria TPX-0022 Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	pexidartinib Sensitive: C2 – Inclusion Criteria pexidartinib Sensitive : C2	pexidartinib Sensitive: C2 – Inclusion Criteria pexidartinib Sensitive : C2
KIT mutation	Acute Myelogenous Leukemia	KIT mutation	Acute Myelogenous Leukemia	avapritinib Sensitive: C2 – Inclusion Criteria avapritinib Sensitive : C2	avapritinib Sensitive: C2 – Inclusion Criteria avapritinib Sensitive : C2
KIT exon 9 mutation	Gastrointestinal Stromal Tumor	KIT exon 9 mutation	Gastrointestinal Stromal Tumor	avapritinib Resistant: C3 – Early Trials avapritinib Resistant : C3	avapritinib Resistant: C3 – Early Trials avapritinib Resistant : C3
MET exon 14 deletion	Non Small Cell Lung Cancer	MET exon 14 deletion	Non Small Cell Lung Cancer	TPX-0022 Sensitive: C3 – Early Trials TPX-0022 Sensitive : C3	TPX-0022 Sensitive: C3 – Early Trials TPX-0022 Sensitive : C3
MET amplification	Colorectal Cancer	MET amplification	Colorectal Cancer	TPX-0022 Sensitive: C3 – Early Trials TPX-0022 Sensitive : C3	TPX-0022 Sensitive: C3 – Early Trials TPX-0022 Sensitive : C3
TMB-L	Pancreatic Cancer	TMB-L	Pancreatic Cancer	nivolumab + BMS-986227 Sensitive: C3 – Early Trials nivolumab + BMS-986227 Sensitive : C3	nivolumab + BMS-986227 Sensitive: C3 – Early Trials nivolumab + BMS-986227 Sensitive : C3
KIT exon 17 mutation	Thymic Carcinoma	KIT exon 17 mutation	Thymic Carcinoma	avapritinib Sensitive: C3 – Early Trials avapritinib Sensitive : C3	avapritinib Sensitive: C3 – Early Trials avapritinib Sensitive : C3
KIT exon 17 mutation	Mucosal Melanoma	KIT exon 17 mutation	Mucosal Melanoma	avapritinib Sensitive: C3 – Early Trials avapritinib Sensitive : C3	avapritinib Sensitive: C3 – Early Trials avapritinib Sensitive : C3
KIT exon 17 mutation	Gastrointestinal Stromal Tumor	KIT exon 17 mutation	Gastrointestinal Stromal Tumor	avapritinib Resistant: C4 – Case Studies avapritinib Resistant : C4	avapritinib Resistant: C4 – Case Studies avapritinib Resistant : C4
KIT exon 11 mutation	Gastrointestinal Stromal Tumor	KIT exon 11 mutation	Gastrointestinal Stromal Tumor	avapritinib Resistant: C4 – Case Studies avapritinib Resistant : C4	avapritinib Resistant: C4 – Case Studies avapritinib Resistant : C4
FLT3 D835Y	Acute Myelogenous Leukemia	FLT3 D835Y	Acute Myelogenous Leukemia	pexidartinib Sensitive: C4 – Case Studies pexidartinib Sensitive : C4	pexidartinib Sensitive: C4 – Case Studies pexidartinib Sensitive : C4
CCND3 T283A	Acute Myelogenous Leukemia	CCND3 T283A	Acute Myelogenous Leukemia	pexidartinib Resistant: C4 – Case Studies pexidartinib Resistant : C4	pexidartinib Resistant: C4 – Case Studies pexidartinib Resistant : C4
CCND3 Q276* + CCND3 S264R	Acute Myelogenous Leukemia	CCND3 Q276* + CCND3 S264R	Acute Myelogenous Leukemia	pexidartinib Resistant: C4 – Case Studies pexidartinib Resistant : C4	pexidartinib Resistant: C4 – Case Studies pexidartinib Resistant : C4
MET H1094Y	Non Small Cell Lung Cancer	MET H1094Y	Non Small Cell Lung Cancer	TPX-0022 Sensitive: C4 – Case Studies TPX-0022 Sensitive : C4	TPX-0022 Sensitive: C4 – Case Studies TPX-0022 Sensitive : C4
MET F1200I	Non Small Cell Lung Cancer	MET F1200I	Non Small Cell Lung Cancer	TPX-0022 Sensitive: C4 – Case Studies TPX-0022 Sensitive : C4	TPX-0022 Sensitive: C4 – Case Studies TPX-0022 Sensitive : C4
MET F1200I	Lung Adenocarcinoma	MET F1200I	Lung Adenocarcinoma	TPX-0022 Sensitive: C4 – Case Studies TPX-0022 Sensitive : C4	TPX-0022 Sensitive: C4 – Case Studies TPX-0022 Sensitive : C4
MET H1094Y	Lung Adenocarcinoma	MET H1094Y	Lung Adenocarcinoma	TPX-0022 Sensitive: C4 – Case Studies TPX-0022 Sensitive : C4	TPX-0022 Sensitive: C4 – Case Studies TPX-0022 Sensitive : C4
FLT3 F691L	Acute Myelogenous Leukemia	FLT3 F691L	Acute Myelogenous Leukemia	pexidartinib Sensitive: D – Preclinical pexidartinib Sensitive : D	pexidartinib Sensitive: D – Preclinical pexidartinib Sensitive : D
PDGFRA mutation	Gastrointestinal Stromal Tumor	PDGFRA mutation	Gastrointestinal Stromal Tumor	AZD1775 + avapritinib Sensitive: D – Preclinical AZD1775 + avapritinib Sensitive : D	AZD1775 + avapritinib Sensitive: D – Preclinical AZD1775 + avapritinib Sensitive : D
KIT mutation	Gastrointestinal Stromal Tumor	KIT mutation	Gastrointestinal Stromal Tumor	AZD1775 + avapritinib Sensitive: D – Preclinical AZD1775 + avapritinib Sensitive : D	AZD1775 + avapritinib Sensitive: D – Preclinical AZD1775 + avapritinib Sensitive : D
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	vorolanib Sensitive: D – Preclinical vorolanib Sensitive : D	vorolanib Sensitive: D – Preclinical vorolanib Sensitive : D
ETV6-NTRK3 fusion	Acute Lymphocytic Leukemia	ETV6-NTRK3 fusion	Acute Lymphocytic Leukemia	OPN-7486 Sensitive: D – Preclinical OPN-7486 Sensitive : D	OPN-7486 Sensitive: D – Preclinical OPN-7486 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	SB939 + pacritinib Sensitive: D – Preclinical SB939 + pacritinib Sensitive : D	SB939 + pacritinib Sensitive: D – Preclinical SB939 + pacritinib Sensitive : D

CSF-1R inhibitor

CSF-1R inhibitor

Associations(37)

Associations
(37)